50
Participants
Start Date
August 19, 2025
Primary Completion Date
August 30, 2031
Study Completion Date
August 30, 2031
ZEN-3694
One ZEN-3694 pill (48 mg) will be taken each day of each BATZEN cycle.
Testosterone cypionate
On day 1 of each BATZEN cycle testosterone cypionate (400 mg) injection to the buttocks will be administered.
Enzalutamide
Enzalutamide 160 mg (four 40 mg capsules) taken daily by mouth on each ZENZA cycle.
Luteinizing hormone-releasing hormone (LHRH) analogue
Patients will continue on ADT with LHRH agonist (i.e. Zoladex, Trelstar, Eligard or Lupron) or LHRH antagonist (Degarelix or Relugolix) if not surgically castrated throughout the duration of the study to inhibit endogenous testosterone production.
RECRUITING
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Collaborators (1)
Zenith Epigenetics
INDUSTRY
National Cancer Institute (NCI)
NIH
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OTHER